LUPUS (2018) 27, 1572
In recent years there has been an increased focus on the role of the blood vessels (and their role in the heightened tendency to clotting) in both Hughes Syndrome and Lupus.
One line of investigation allows a place for statin treatment as possible protection in this situation. The jury is out. However, this small study from Poland found that a 1-month course of simvastatin led to a reduction in a number of inflammatory markers, and, somewhat surprisingly, to a reduction of anticardiolipin antibodies.
LUPUS (2018) 27, 1404-1414
Our original papers describing the Antiphospholipid Syndrome in 1983 used the title “Thrombosis, abortion, cerebral disease and the lupus anticoagulant”.
In many ways the thrombosis and abortion aspects of Hughes Syndrome have received the lion’s share of recognition. Yet the ‘neurological disease’ aspect is equally important.
This detailed review by Ricarte and colleagues from Sao Pauli, Brazil, provides a clear and comprehensive review of the topic, from aetiology to treatment. A valuable paper.
LUPUS (2018) 27, 1402-1404
This short leader follows a detailed review on Plaquenil and the retina.
Plaquenil is a marvellous medicine used worldwide in lupus, Sjogren’s and (increasingly) in Hughes Syndrome.
Now that the drug is frequently used long term (e.g., over 20 years), a recent review from the ophthalmology world advises more frequent eye examinations. And, for those of us using the drug, a dose of 1/day (200 mg daily) seems more appropriate than higher doses
LUPUS (2018) 27, 1303-13
This is an important paper, looking at graft survival periods dating back to 1979 (Mexico).
The good news is that Lupus Nephritis graft recipients have satisfactory outcomes, and similar to those of patients with other causes.
LUPUS (2018) 27, 1207-1217
Traditionally, it has been reported that Lupus is rare in sub-Saharan Africa. But studies from a number of African centres are now being published.
This report, from Durban, included 105 patients (49.1 Indians and 45.3% African blacks). The report concluded “In conclusion, our multi-ethnic Lupus Nephritis cohort shows a good response to treatment”.
LUPUS (2018) 27, 1123-1129
On what I call a ‘Friday night’ case of a sick Lupus patient admitted to my hospital with fever, one of the first tests I look for is the CRP level. A high CRP level points strongly towards infection. An easy lesson I used to teach my students was: High ESR/Low CRP – lupus, high ESR/high CRP – infection. Of course, there are exceptions, but the rule has proved useful over the years.
This excellent article from Michigan retrospectively looks at SLE patients with a temperature of over 100.3 F confirmed the idea of an ESR/CRP ratio as a diagnostic aid, and, by analogy, the importance of CRP – this “mysterious” protein.
LUPUS (2018) 27, 1247-1248
This interesting study from Vancouver studied 3632 Lupus patients (and 18060 controls) estimating health care costs over a 5-year period. Not unexpectedly, even years before diagnosis, SLE patients incurred significantly elevated medical costs compared with general population.
LUPUS (2018) 27, 1225-1239
This is a detailed review from Poland on a topic that is becoming increasingly studied. Heart rate and hart rate variability are controlled by the autonomic nervous system (the “automatic” organs such as the lungs, the heart, the blood vessels, the skin temperature and the gut).
It is interesting to know that a number of studies are appearing linking autonomic dysfunction (such as POTS: Paroxysmal orthostatic tachycardia syndrome) with certain autoimmune disorders – Sjogren’s Syndrome, Hughes Syndrome and Lupus. Measurement of heart rate variability could prove a useful clinical tool.
LUPUS (2018) 27 1045-1046
This interesting letter to Lupus highlighted the influence of the media, and in this case, the public disclosure of the lupus diagnosis by Selina Gomez on public awareness.
LUPUS (2018) 27, 1030-1038
This study of over a thousand lupus patients came from a respected lupus group in Cairo, studied and treated between 1980 and 2016.
The results were in agreement with other studies conducted in the middle East. However, one striking difference was that major organ involvement was exceptionally low.
LUPUS (2018) 27, 1012-1017
Hydroxychloroquine has become an important drug in lupus, especially in the long-term management of mild to moderate cases. However, its use in pregnancy is limited, both by the patients’ desire to avoid all medication, but also, significantly, by the opinion of many doctors that hydroxychloroquine is contraindicated – stopped at pregnancy onset – with the almost expected flare three months into the pregnancy.
This study from Boston of 5,300 lupus patients found that the percentage of patients continuing hydroxychloroquine during pregnancy rose from 12.4% (in 2001) to 37.7% in 2015. Still a low figure.
LUPUS (2018) 27, 703-707
Hydroxychloroquine (Plaquenil) is a vital drug in the management of lupus – so much so that many publications recommend lifelong use. Consequently, having to stop taking the drug because of allergic/adverse reaction is a major issue.
In this study from Jerusalem, 13 such patients underwent a gradual desensitisation regime, starting with highly diluted doses of hydroxychloroquine. In 12 of the 13 the patients were subsequently able to continue on standard hydroxychloroquine doses.
LUPUS (2018) 27 858-863
In this study 508 patients with APS were studied, 360 with primary APS (PAPS) and 148 with APS associated with SLE (SAPS).
This important study showed a strong association between skin manifestations (notably livedo) and neurological involvement (notably stroke).
LUPUS (2018) 27, 536-544
This large group of Latin American physicians from centres in South America analysed factors prior to flares of lupus.
A total of 465 cases and controls were studied. Older age at diagnosis and more frequent antimalarial use were protective of flares while azathioprine use, and high disease activity were predictive of flares.
LUPUS (2018) 27, 665-699
From the very earliest description of the antiphospholipid syndrome it has been recognised that 'non-thrombotic' features as well as thrombotic can occur in Hughes Syndrome.
This study (from Turkey) compared SLE patients with and without antiphospholipid antibodies (aPL). Livedo, neurologic involvement and low platelets were more common in aPL positive SLE patients. Face rash, arthritis and pleurisy were more common in SE/aPL negative patients.
LUPUS (2018) 27, 681-687
This was the result of a 2014 survey of 2527 member of the national charity LUPUS UK.
LUPUS (2018) 27, 60-65
Tacrolimus, an immunosuppressive drug has been around a long time, but has not become one of the leading drugs in the lupus world.
This study from China provides a reminder that 'older' drugs may have a significant role.
This study looked at 20 lupus patients with low platelets (often a difficult and stubborn problem). After one month of Tacrolimus treatment, 3 patients achieved a complete response, 14 patients a partial response and 3 did not respond. "After 3 months of Tacrolimus treatment, all patients were significantly improved".
LUPUS (2018) 27, 3-5
For those wishing to catch up on the important (and ground-breaking) observations linking rheumatology and orthopaedics to the antiphospholipid syndrome, there is no better place to start.
This review by Noureldine and Uthman, from the excellent unit in Beirut, provides a concise overview of the clinical picture – at least as we understand it in 2018.
Clearly avascular necrosis (AVN) is a clearly related problem, but multiple fractures for example are now well recognised.
So, you have Hughes syndrome? Have you ever suffered a bone fracture? A “yes” answer is opening up a whole new avenue of research into fracture risk.
Lupus (2014) 23, 400-406
I wish to start by thanking the organizers of this, the 14th International Congress on Antiphospholipid Antibodies, for the honour of giving this opening talk. I will talk briefly about the past and crystal-gaze briefly into the future. But my main focus is on the present – largely through the eyes of a clinician, punctuated from time to time by doctors’ letters – five doctors’ letters, in fact..
Lupus (2017) 26, 3-5
Rolando Cimaz and his team have been at the forefront of studies of epilepsy in lupus and antiphospholipid syndrome. In this article, part of the LUPUS ‘Update’ series, they have reviewed he recent published literature.
The main conclusions were that seizures tended to occur early in the course of the disease, reported in between 6% and 12.,5% of lupus patients. As expected there was a strong link with the presence of antiphospholipid antibodies. In particular, anti-B2GP1 antibodies were very strongly associated patients with this antibody being 11 times more likely to have seizures.
LUPUS (2017) 26, 529-536
This is a very detailed review of the etiology and treatment of both lupus and antiphospholipid syndrome.
An overall incidence rate of between 3% and 20%, was reported in lupus, especially in the first 5 years of the disease.
While traditional factors of stroke such as smoking diabetes and hypertension contributed to some cases, by far the strongest link was with antiphospholipid antibodies (aPL). The mechanism is considered thrombotic, not haemorrhagic. No surprisingly the best treatment results have been with Warfarin, with an INR of 3.0-4.0.
LUPUS (2017) 26, 237-239
In the USA, stillbirth happens in about 6.4 per 1000 births.
Recent reports quoted by Ware Branch’s group in Utah (one of the world’s leaders in this field) found that antiphospholipid antibodies were found in 9.6% of stillbirth cases. When other obstetric complications were excluded, about 14% were thought to be secondary to Aps. Within this group, the presence of either a positive lupus anticoagulant, or a ‘triple positive’ (aCL, LA and ant-B2GP1) antibody profile suggested a higher risk.
While the linking of antiphospholipid antibody with stillbirth is another potentially massive advance in obstetrics, the data does require further properly controlled trials “before novel therapies are accepted”.